Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MRC Technology

- PMLiVE

Elan buys into GSK-partnered Theravance programmes for $1bn

Takes a royalty interest in four respiratory drugs

- PMLiVE

GSK wins US approval for Seretide successor Breo Ellipta

FDA gives green light to COPD combination

- PMLiVE

Redx Pharma to open research centre at AstraZeneca’s Alderley Park site

Will focus on hard-to-treat infections

- PMLiVE

GSK submits COPD drug in US and EU

Umeclidinium bromide intended as monotherapy for lung condition

- PMLiVE

Union calls on AstraZeneca to reconsider Alderley Park plans

Unite says move to Cambridge will take years to deliver value

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

GSK buoyed by FDA panel backing for Advair successor

Committee votes in favour of Breo’s use in respiratory condition COPD

- PMLiVE

AstraZeneca signs cancer biomarkers discovery deal

Partners with UK firm on personalised oncology drug research

- PMLiVE

BMS and Vertex partner on oral hepatitis treatment

Will investigate combination of daclatasvir and VX-135

- PMLiVE

BMS names Francis Cuss as new R&D chief

Will replace Elliott Sigal who retires

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links